Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial

被引：0

作者：

Siegel, David Samuel DiCapua

Richardson, Paul Gerard Guy

Vij, Ravi

Hofmeister, Craig C.

Baz, Rachid C.

Jagannath, Sundar

Chen, Christine

Lonial, Sagar

Jakubowiak, Andrzej J.

Bahlis, Nizar J.

Song, Kevin W.

Belch, Andrew

Raje, Noopur S.

Shustik, Chaim

Lentzsch, Suzanne

Chen, Min

Zaki, Mohamed H.

Anderson, Kenneth Carl

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Washington Univ, St Louis, MO USA

[4] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[6] Mt Sinai Med Ctr, New York, NY 10029 USA

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] Emory Univ, Sch Med, Atlanta, GA USA

[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[10] Univ Calgary, Calgary, AB, Canada

[11] Vancouver Gen Hosp, Vancouver, BC, Canada

[12] Univ Alberta, Edmonton, AB, Canada

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada

[15] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[16] Celgene Corp, Summit, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8588

引用

页数：1

共 50 条

[31] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI)
Weisel, Katja C.
Dimopoulos, Meletios A.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Weisel, K.
Dimopoulos, M.
Moreau, P.
Lacy, M.
Song, K.
Delforge, M.
Karlin, L.
Goldschmidt, H.
Banos, A.
Oriol, A.
Alegre, A.
Chen, C.
Cavo, M.
Garderet, L.
Ivanova, V.
Martinez-Lopez, J.
Yu, X.
Sternas, L.
Jacques, C.
Zaki, M.
San Miguel, J.
HAEMATOLOGICA, 2013, 98 : 105 - 105
[33] The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in refractory or relapsed and refractory multiple myeloma
Dimopoulos, Meletios A.
Weisel, Katja C.
Cavo, Michele
Corradini, Paolo
Delforge, Michel
Morgan, Gareth J.
Hansson, Markus
Palumbo, Antonlo
Oclo, Enrique M.
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Leupin, Nicolas
Nikolova, Zariana G.
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (Pi) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed
Siegel, David
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Ketih
Kaya, Hakan
Sebag, Michael
Samaras, Christy
Malek, Ehsan
Talamo, Giampaolo
Seet, Christopher S.
Mouro, Jorge
Zafar, Faiza
Chung, Weiyuan
Srinivasan, Shankar
Qian, Max
Agarwal, Amit
Thakurta, Anjan
Bahlis, Nizar J.
BLOOD, 2017, 130
[35] Phase 2 Study of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Following Second-Line Lenalidomide (LEN)-Based Treatment (Tx) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): An Updated Analysis of Efficacy and Safety
Siegel, David S.
Schiller, Gary J.
Song, Kevin
Agajanian, Richy
Stockerl-Goldstein, Keith
Kaya, Hakan
Sebag, Michael
Reu, Frederic J.
Malek, Eshan
Mouro, Jorge
Chung, Weiyuan
Srinivasan, Shankar
Qian, Max
Rizvi, Syed
Thakurta, Anjan
Bahlis, Nizar J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E141 - E141
[36] MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low -Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis
Sonneveld, Pieter
Weisel, Katja C.
Li, Yan
Kueenburg, Elisabeth
Collins, Shona
Di Micco, Antonia
Rosettani, Barbara
Bacon, Pamela
Dimopoulos, Meletios A.
BLOOD, 2017, 130
[37] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
Siegel, David Samuel DiCapua
Schiller, Gary J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo
Reece, Donna Ellen
Zafar, Faiza
Chung, Weiyuan
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Richardson, Paul G.
Rocafiguera, Albert Oriol
Beksac, Meral
Liberati, Anna Marina
Galli, Monica
Schjesvold, Fredrik
Lindsay, Jindriska
Weisel, Katja
White, Darell
Facon, Thierry
San-Miguel, Jesus
Sunami, Kazutaka
O'Gorman, Peter
Sonneveld, Pieter
Yu, Xin
Doerr, Thomas
Bensmaine, Amine
Zaki, Mohamed H.
Anderson, Kenneth Carl
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[39] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M. A.
Weisel, K.
Song, K. W.
Delforge, M.
Karlin, L.
Goldschmidt, H.
Moreau, P.
Banos, A.
Oriol, A.
Garderet, L.
Cavo, M.
Ivanova, V.
Alegre, A.
Martinez-Lopez, J.
Chen, C. I.
Spencer, A.
Knop, S.
Bahlis, N. J.
Renner, C.
Yu, X.
Hong, K.
Sternas, L.
Jacques, C.
Zaki, M. H.
San Miguel, J. F.
HAEMATOLOGICA, 2014, 99 : 365 - 365
[40] MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT
Matous, J.
Siegel, D.
Duong, H.
Kasserra, C.
Sternas, L.
Jacques, C.
Klesczewski, K.
Zaki, M.
Shah, J.
HAEMATOLOGICA, 2013, 98 : 323 - 323

← 1 2 3 4 5 →